<code id='C20A374A5F'></code><style id='C20A374A5F'></style>
    • <acronym id='C20A374A5F'></acronym>
      <center id='C20A374A5F'><center id='C20A374A5F'><tfoot id='C20A374A5F'></tfoot></center><abbr id='C20A374A5F'><dir id='C20A374A5F'><tfoot id='C20A374A5F'></tfoot><noframes id='C20A374A5F'>

    • <optgroup id='C20A374A5F'><strike id='C20A374A5F'><sup id='C20A374A5F'></sup></strike><code id='C20A374A5F'></code></optgroup>
        1. <b id='C20A374A5F'><label id='C20A374A5F'><select id='C20A374A5F'><dt id='C20A374A5F'><span id='C20A374A5F'></span></dt></select></label></b><u id='C20A374A5F'></u>
          <i id='C20A374A5F'><strike id='C20A374A5F'><tt id='C20A374A5F'><pre id='C20A374A5F'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:6475
          Miniature people figurines standing in a group looking down. -- health tech coverage from STAT
          Adobe

          In less than two years, digital health’s high-flying class of public debuts have landed with a resounding thud.

          Accelerated by the pandemic’s forced adoption of telehealth and other digital health solutions, 2021 saw more than 30 health technology startups go public, raising hundreds of millions and in some cases billions of dollars. Today, three members of the class of 2021 have gone bankrupt. Twelve companies have lost more than 90% of their initial value, including Bright Health Group, Cue Health, and Better Therapeutics. And dangerously low reserves have inspired desperate moves to slash costs, drum up liquidity, and find buyers.

          advertisement

          Most recently, the bankruptcy of digital primary care company Babylon Health has drawn attention to the plight of newly-public health tech companies, and how the froth of dealmaking at the height of the pandemic led to overblown valuations. Before its debut in June 2021, Babylon was valued at $4.2 billion; after filing for bankruptcy in August, its U.K. telemedicine business was sold for just over $600,000.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Merus drug and Keytruda shrank tumors in patients with head and neck cancer
          Merus drug and Keytruda shrank tumors in patients with head and neck cancer

          ThisimmunofluorescenceimageshowsTcells(ingreenandyellow)inthemicroenvironmentofaheadandnecksquamousc

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb